8-K: Evofem Biosciences Licenses SOLOSEC Rights in Middle East to Pharma 1

Evofem Biosciences grants Pharma 1 Drug Store exclusive rights to market and distribute SOLOSEC in the Middle East, targeting regulatory submission in the UAE by mid-2025.

Summary

• Evofem Biosciences has entered into a License and Supply Agreement with Pharma 1 Drug Store for the Middle East rights to SOLOSEC.
• Pharma 1 gains exclusive rights to develop, market, and distribute SOLOSEC in the UAE, Kuwait, Saudi Arabia, Qatar, and other Middle Eastern countries for five years.
• Pharma 1 is expected to file for regulatory approval in the UAE by mid-2025.
• Evofem will receive an upfront payment, regulatory milestone payments, and sales-based milestone payments.
• Once approved, Evofem will supply SOLOSEC to Pharma 1 at cost-plus.
• The agreement covers the treatment of bacterial vaginosis (BV) and trichomoniasis, common sexual health conditions in the region.
• Studies indicate a BV prevalence ranging from 25% to 41% in the Middle East and North Africa (MENA) region.
• The WHO estimated 156.3 million new cases of trichomoniasis worldwide in 2020.
• A meta-analysis found that approximately 4.7% of women in the general population in MENA are affected by trichomoniasis.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the licensing agreement expected to expand market reach and generate revenue for Evofem. The partnership with Pharma 1 is viewed favorably, and the focus on addressing unmet needs in women's sexual health is a positive development.

Positives

• Evofem gains access to the Middle Eastern market for SOLOSEC through an established partner.
• The agreement provides Evofem with upfront and milestone payments, as well as a cost-plus supply arrangement.
• SOLOSEC offers a convenient single-dose oral treatment for BV and trichomoniasis.
• Pharma 1 is responsible for regulatory approvals, distribution, sales, and marketing in the region.
• The partnership expands Evofem's relationship with Pharma 1 beyond PHEXXI.

Risks

• Regulatory approval in the UAE and other Middle Eastern countries is not guaranteed.
• The commercial success of SOLOSEC in the region depends on Pharma 1's ability to effectively market and distribute the product.
• The agreement is subject to customary representations, warranties, and indemnities, which could lead to potential liabilities.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Pharma 1 aims to file for regulatory approval of SOLOSEC in the UAE by mid-2025, with plans to launch and commercialize the product in the region.

Management Comments

• Abdulwahab Atfah, CEO of Pharma 1 Drug Store, stated that SOLOSEC offers a convenient one-and-done oral treatment for two common sexual health conditions.
• Saundra Pelletier, CEO of Evofem, expressed confidence that Pharma 1 is the right partner to effectively launch and commercialize SOLOSEC in the UAE and surrounding region.

Industry Context

This agreement reflects a growing interest in addressing women's sexual and reproductive health needs in the Middle East, with a focus on providing convenient and effective treatments for common infections like bacterial vaginosis and trichomoniasis.

Comparison to Industry Standards

• Licensing agreements for pharmaceutical products are common in the industry, allowing companies to expand their market reach and leverage the expertise of local partners.
• The cost-plus supply arrangement is a typical model for ensuring profitability for the manufacturer while allowing the distributor to manage pricing and sales in the local market.
• The milestone payments structure incentivizes the partner to achieve regulatory and commercial success.
• Comparable companies that engage in similar licensing agreements include Organon, Teva, and Mylan.

Stakeholder Impact

• Shareholders: Positive impact due to potential revenue generation and market expansion.
• Employees: Potential for increased job security and growth opportunities.
• Customers: Access to a convenient and effective treatment for BV and trichomoniasis.
• Suppliers: Potential for increased demand for SOLOSEC.
• Creditors: Positive impact due to improved financial outlook for Evofem.

Next Steps

• Pharma 1 will file for regulatory approval of SOLOSEC in the UAE.
• Pharma 1 will develop a Development Plan to pursue governmental approval of SOLOSEC in the Territory.
• Evofem will supply SOLOSEC to Pharma 1 for sale in the Territory once approved.
• Licensee shall provide Licensor with a forecast of requirements for Licensed Products for the eighteen (18) -month period following receipt of such Governmental Approval.

Key Dates

Keywords

SOLOSEC, Evofem Biosciences, Pharma 1, Middle East, License Agreement, Bacterial Vaginosis, Trichomoniasis, Sexual Health, Regulatory Approval, Distribution